No Data
No Data
Express News | Xilio Therapeutics Shares Are Trading Lower After the Company Reported Initial Data From Its Ongoing Phase 2 Clinical Trial Evaluating Vilastobart in Combination With Atezolizumab
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Xilio Therapeutics Advances With Phase 2 Trial Data
Express News | Xilio Therapeutics Inc - Low Incidence of Immune-Related Adverse Events Reported
Express News | Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (Xtx101), a Tumor-Activated Anti-Ctla-4, in Combination With Atezolizumab in Patients With Metastatic Microsatellite Stable Colorectal Cancer
Press Release: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
70102771 : key word missing is “positive” thats what people want to see.